MINDACT Study Shows MammaPrint® Provides Widespread Health System Cost Savings
Analysis Published in European Journal of Cancer Use of MammaPrint Read More
Agendia Included on the 2020 Inc. 5000 List With Three-Year Revenue Growth Approaching 90%
Inc. Magazine Unveils Its Annual List of America’s Fastest-Growing Private Read More
Agendia Expands Management Team to Meet Company Momentum, Appoints Brian Dow as Chief Financial Officer
Chief Operating Officer Kurt Becker to Take on Broadened Role Read More
Agendia Publishes Unprecedented Full Genome Dataset from MINDACT Trial for the Advancement of Translational Research in Communications Biology
PRESS RELEASE Irvine, California., July 27, 2020 – Agendia, Inc., a Read More
General Standby Statement
Agendia, Inc. has entered into a Settlement Agreement with the Read More
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
PRESS RELEASE Presentations outline how BluePrint® genomic testing enables further Read More
Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT Read More
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
PRESS RELEASE Data adds to the growing body of evidence Read More
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
